Sunrest Lifescience Completes ₹15.02 Crore Rights Issue

Jyoti Rathi - Kolkata Bureau Jun 26, 2026 1,350 Views

Sunrest Lifescience Limited has successfully raised ₹15.02 crore through a 1:1 rights issue, concluding on April 30, 2026. The funds will primarily support the company’s manufacturing expansion by financing new plant and machinery for its production facility, alongside meeting working capital requirements and general corporate needs for the 2026-27 fiscal year.

MUMBAI — Sunrest Lifescience Limited has officially concluded its rights issue, successfully raising ₹15.02 crore to strengthen its financial position and support operational growth. The company, which specializes in the marketing of a broad range of pharmaceutical and nutraceutical products, issued 4,291,200 equity shares at a price of ₹35 per share to its existing shareholders.

The rights issue, which opened for subscription on April 2, 2026, and closed on April 30, 2026, was conducted on a 1:1 entitlement ratio. This means eligible shareholders were offered one new equity share for every fully paid-up share held as of the record date on March 23, 2026.

Strategic Allocation of Funds

According to the company’s official Letter of Offer, the capital infusion is earmarked for specific growth-oriented objectives. Sunrest Lifescience plans to utilize the funds as follows:

Manufacturing Expansion: Approximately ₹6.85 crore will be directed toward funding a subsidiary to purchase new plant and machinery for a production facility.
Working Capital: Around ₹5.00 crore has been allocated to meet the company’s ongoing working capital requirements.
General Corporate Purposes: The remaining ₹3.17 crore is reserved for general corporate use to support business continuity and administrative stability.

Market Context and Performance

Sunrest Lifescience operates primarily through a third-party supply management model, partnering with over 40 pharmaceutical manufacturers across India, including its group entity, Trilend Pharmaceuticals. The company’s portfolio encompasses a wide array of therapeutic segments, including antibacterial, antidiabetic, and cardiovascular care, as well as nutraceuticals and dental care products.

The rights issue was listed on the National Stock Exchange (NSE) on May 6, 2026. Following the closure of the subscription period, the company moved forward with the allotment and credit of shares to the demat accounts of successful applicants in early May.

Official Sources

According to regulatory filings submitted to the National Stock Exchange (NSE), the rights issue process adhered to all compliance standards set by the Securities and Exchange Board of India (SEBI). Skyline Financial Services Pvt. Ltd. served as the registrar for the issue, managing the electronic credit of Rights Entitlements (REs) and the final share allotment process.

"Organizers stated that the capital raised through this rights issue will provide the necessary liquidity to enhance the company's manufacturing footprint and strengthen its competitive position within the pharmaceutical marketing landscape."

Why It Matters

For investors and stakeholders, this capital raise is a significant milestone as Sunrest Lifescience seeks to transition toward greater control over its supply chain through manufacturing investments. By increasing its stake in plant and machinery, the company aims to reduce its reliance on third-party manufacturers, potentially improving margins and operational control in the long term.

Key Facts at a Glance

Total Amount Raised: ₹15.02 crore.
Issue Price: ₹35 per share (Face Value: ₹10).
Subscription Window: April 2, 2026, to April 30, 2026.
Entitlement Ratio: 1:1 (one rights share for every existing share held).
Primary Objective: Funding new plant and machinery and meeting working capital needs.

Frequently Asked Questions (FAQ)

1. What was the purpose of the Sunrest Lifescience rights issue?

The funds are primarily intended to support the establishment of a new production facility through a subsidiary, meet working capital needs, and address general corporate expenses.

2. What happens to shareholders who did not participate in the rights issue?

Shareholders who chose not to subscribe to the rights issue saw their existing shareholding diluted. Their unused Rights Entitlements (REs) lapsed and were extinguished after the closing date of the issue.

3. Is Sunrest Lifescience expanding its own manufacturing capabilities?

Yes, a portion of the proceeds (₹6.85 crore) is specifically allocated to purchasing plant and machinery, signaling a strategic shift toward strengthening its internal production capacity.

4. Where can I find the official records of this rights issue?

Details of the issue, including the Letter of Offer and allotment status, are available on the NSE India website under the company’s corporate filings section.